Overview

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Docetaxel
Irinotecan